Letrozole

Generic Name: Letrozole

Brand Names: Femara, Kisqali Femara Co-pack

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₁N_₅

CAS Number: 112809-51-5

Unique Ingredient Identifier: 7LKK855W8I

Background: Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication: Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...

Associated Conditions: Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer

Associated Therapies: -

Clinical Trials

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Lapatinib
Drug: Letrozole
Drug: Placebo

First Posted Date: 2003-11-26

Last Posted Date: 2021-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1286

Registration Number: NCT00073528

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

First Posted Date: 2003-11-13

Last Posted Date: 2013-02-21

Lead Sponsor: Novartis

Registration Number: NCT00014638

Locations: 🇺🇸
Cancer Research Network, Inc., Hollywood, Florida, United States
🇺🇸
Good Samaritan Medical Center, West Palm Beach, Florida, United States
🇺🇸
Carle Cancer Center, Urbana, Illinois, United States

and more 17 locations

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Letrozole / Temsirolimus (CCI-779)
Drug: Letrozole

First Posted Date: 2003-06-13

Last Posted Date: 2011-04-15

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 108

Registration Number: NCT00062751

Letrozole After Tamoxifen in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole
Other: placebo

First Posted Date: 2003-01-27

Last Posted Date: 2020-09-16

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 5187

Registration Number: NCT00003140

Locations: 🇨🇦
The Moncton Hospital, Moncton, New Brunswick, Canada
🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

and more 54 locations

Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: tamoxifen citrate
Drug: letrozole

First Posted Date: 2003-01-27

Last Posted Date: 2017-12-12

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 8028

Registration Number: NCT00004205

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷
Institut Bergonie, Bordeaux, France
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Phase 3

Completed

Conditions: Breast Neoplasms
Osteoporosis

Interventions: Drug: Zoledronic Acid
Drug: Letrozole

First Posted Date: 2002-11-20

Last Posted Date: 2014-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 602

Registration Number: NCT00050011

Locations: 🇺🇸
FL Community Cancer Center, Brooksville, Florida, United States
🇺🇸
Eastern Connecticut Hematology/Oncology Associates, Norwich, Connecticut, United States
🇺🇸
Elmhurst Memorial Hospital, Elhurst, Illinois, United States

and more 41 locations

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms
Neoplasms, Hormone-dependent

Interventions: Drug: atamestane
Drug: letrozole
Drug: aromatase inhibition
Drug: toremifene
Procedure: hormone therapy
Procedure: endocrine therapy
Procedure: antiestrogen therapy

First Posted Date: 2002-08-27

Last Posted Date: 2015-07-31

Lead Sponsor: Intarcia Therapeutics

Target Recruit Count: 865

Registration Number: NCT00044291

Locations: 🇺🇦
Kharkov Medical Academy of Postgraduate Education, Oncology and Pediatric Oncology Department. Clinical Facility: Kharkov Regional Clinical Oncology Dispensary, Chemotherapy Department, Kharkov, Ukraine
🇺🇦
Odessa State Medical University, Oncology Department. Clinical Facility: Odessa Regional Oncology Center, Chemotherapy Department, Odessa, Ukraine
🇷🇺
V. Novgorod Regional Oncology Center, Department of Chemotherapy, V. Novgorod, Russian Federation

and more 60 locations